These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37207192)

  • 1. Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease.
    Li Y; Zhu N; Cui X; Lin Y; Li X
    Front Cell Infect Microbiol; 2023; 13():1178590. PubMed ID: 37207192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ursodeoxycholic acid on preventing SARS-CoV-2 infection in patients with liver transplantation: a multicenter retrospective cohort study.
    Hu L; Zhang H; Huang C; Shen T; Feng Z; Mu F; Xu L; Lin Y; Yue C; Guo K; Tian M; Shi J; Zhang C; Wen P; Cao S; Wang Y; Zhang J; Shi X; Wang Z; He Y; Zhang X; Liu X; Lv Y; Liu Z; Guo W; Wang B
    QJM; 2024 Jun; 117(5):339-347. PubMed ID: 37950449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholic acid is associated with a reduction in SARS-CoV-2 infection and reduced severity of COVID-19 in patients with cirrhosis.
    John BV; Bastaich D; Webb G; Brevini T; Moon A; Ferreira RD; Chin AM; Kaplan DE; Taddei TH; Serper M; Mahmud N; Deng Y; Chao HH; Sampaziotis F; Dahman B
    J Intern Med; 2023 May; 293(5):636-647. PubMed ID: 37018129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the protective effectiveness and risk factors of ursodeoxycholic acid on COVID-19 among outpatients.
    Li D; Fang Q; Chen Z; Tang J; Tang H; Cai N; Qiu K; Zhu M; Yang X; Yang L; Yang Y; Huang Y; Lei X; Zhang H; Lin Q; Mao Q; Xu T; Li Y; Zheng Y; Peng M; Hu P
    Front Pharmacol; 2024; 15():1381830. PubMed ID: 39144619
    [No Abstract]   [Full Text] [Related]  

  • 5. Ursodeoxycholic acid administration did not reduce susceptibility to SARS-CoV-2 infection in children.
    Liu T; Wang JS
    Liver Int; 2023 Sep; 43(9):1950-1954. PubMed ID: 37381749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients.
    Colapietro F; Angelotti G; Masetti C; Shiffer D; Pugliese N; De Nicola S; Carella F; Desai A; Ormas M; Calatroni M; Omodei P; Ciccarelli M; Aliberti S; Reggiani F; Bartoletti M; Cecconi M; Lleo A; Aghemo A; Voza A
    Viruses; 2023 Aug; 15(8):. PubMed ID: 37632080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodeoxycholic acid does not affect the clinical outcome of SARS-CoV-2 infection: A retrospective study of propensity score-matched cohorts.
    Marrone G; Covino M; Merra G; Piccioni A; Amodeo A; Novelli A; Murri R; Pompili M; Gasbarrini A; Franceschi F
    Liver Int; 2024 Jan; 44(1):83-92. PubMed ID: 37735968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholic acid may protect from severe acute respiratory syndrome coronavirus 2 Omicron variant by reducing angiotensin-converting enzyme 2.
    Lee K; Na Y; Kim M; Lee D; Choi J; Kim G; Kim MS
    Pharmacol Res Perspect; 2024 Apr; 12(2):e1194. PubMed ID: 38573021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-word setting.
    Corpechot C; Verdoux M; Frank-Soltysiak M; Duclos-Vallée JC; Grimaldi L
    J Med Virol; 2024 Jan; 96(1):e29418. PubMed ID: 38240338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver.
    Arat M; Idilman R; Soydan EA; Soykan I; Erden E; Karayalçin S; Akan H
    Clin Transplant; 2005 Dec; 19(6):798-803. PubMed ID: 16313328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid does not reduce SARS-CoV-2 infection in newly allogeneic hematopoietic stem cell transplantation recipients: a prospective NICHE cohort.
    Gao H; Wang J; Zheng X; Pei X; Zheng Y; Zhai W; Zhang R; Chen X; Ma Q; Wei J; Yang D; Pang A; He Y; Feng S; Cao Y; Jiang E
    Front Cell Infect Microbiol; 2024; 14():1324019. PubMed ID: 38505288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.
    Desmond CP; Wilson J; Bailey M; Clark D; Roberts SK
    Liver Int; 2007 Dec; 27(10):1402-8. PubMed ID: 18036103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
    Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
    J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Association of Ursodeoxycholic Acid Use With Colorectal Cancer Risk: A Nationwide Cohort Study.
    Huang WK; Hsu HC; Liu JR; Yang TS; Chen JS; Chang JW; Lin YC; Yu KH; Kuo CF; See LC
    Medicine (Baltimore); 2016 Mar; 95(11):e2980. PubMed ID: 26986110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease.
    Lirussi F; Beccarello A; Bortolato L; Morselli-Labate AM; Crovatto M; Ceselli S; Santini G; Crepaldi G
    Liver; 1999 Oct; 19(5):381-8. PubMed ID: 10533795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis.
    Fang YQ; Lv DX; Jia W; Li J; Deng YQ; Wang Y; Yu M; Wang GQ
    Medicine (Baltimore); 2014 Oct; 93(20):e104. PubMed ID: 25365404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of ursodeoxycholic acid in prevention of methotrexate-induced liver toxicity.
    Uraz S; Tahan V; Aygun C; Eren F; Unluguzel G; Yuksel M; Senturk O; Avsar E; Haklar G; Celikel C; Hulagu S; Tozun N
    Dig Dis Sci; 2008 Apr; 53(4):1071-7. PubMed ID: 17934844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
    Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A
    Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of ursodeoxycholic acid in patients with liver disease.
    Angulo P
    Curr Gastroenterol Rep; 2002 Feb; 4(1):37-44. PubMed ID: 11825540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.